ArticleNaunyn-Schmiedeberg's archives of pharmacology1991
The dualistic mode of action of the vasodilator drug, nicorandil, differentiated by glibenclamide in 86Rb flux studies in rabbit isolated vascular smooth muscle.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 14 citations in OpenAlex.
- Effects of the K+ channel blocker tedisamil on 86Rb efflux induced by cromakalim, high potassium and noradrenaline, and on mechanical tension in rabbit isolated vascular smooth muscle.Naunyn-Schmiedeberg's archives of pharmacology · 1992Article
- Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats.British journal of pharmacology · 1992Article
- 2-Nicotinamidoethyl acetate (SG-209) is a potassium channel opener: structure activity relationship among nicorandil derivatives.Naunyn-Schmiedeberg's archives of pharmacology · 1991Article
- Nicorandil: A drug with ongoing benefits and different mechanisms in various diseased conditions.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) In rabbit isolated aorta, the effects of the antianginal drug, nicorandil, of the K+ channel opener, cromakalim, and of the nitrovasodilator, sodium nitroprusside, on 86Rb efflux and on contractile force were compared. (2) In ion flux studies using 86Rb as a marker of K+ ions, both nicorandil and cromakalim, but not sodium nitroprusside, increased the efflux of 86Rb in non-stimulated preparations. The increase of membrane K+ conductance induced by nicorandil and cromakalim was totally suppressed by 10(-5) mol/l of the sulfonylurea derivative, glibenclamide. (3) The vasoconstrictor drug, noradrenaline (3 x 10(-7) mol/l), effectively increased the rate of 86Rb efflux. This stimulatory response was unaffected by glibenclamide, but was totally inhibited by Ca2+ depletion suggesting that the activation of Ca2(+)-sensitive K+ channels was responsible for this action of noradrenaline. (4) Sodium nitroprusside and nicorandil, the latter in the presence of glibenclamide to suppress the glibenclamide-sensitive stimulatory component on 86Rb efflux, antagonized the noradrenaline-induced increase in 86Rb efflux, while cromakalim in the presence of glibenclamide had no effect. (5) All of the vasodilators relaxed rabbit aortic strips contracted by 10(-7) mol/l noradrenaline in a concentration-dependent manner. (6) The vasodilatory response to cromakalim was antagonized by glibenclamide, whereas the relaxant action of nicorandil and of sodium nitroprusside remained unaffected. (7) These results demonstrate that under particular experimental circumstances, nicorandil can behave in vascular smooth muscle both as an opener of glibenclamide-sensitive K+ channels, and as a directly acting nitrovasodilator which acts via reduction of cellular calcium levels.(ABSTRACT TRUNCATED AT 250 WORDS)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.